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ABSTRACT 
Background In a hypothesis generating study by my colleagues a 7-fold increase in the 
risk of esophageal adenocarcinoma (EAC) was found in a cohort of individuals born 
preterm or with a low birth weight. Preterm born individuals regurgitate more than term 
born infants, and infant gastroesophageal reflux disease (GERD) might continue into 
childhood and even adulthood. GERD, a major public health problem in adult 
westernized populations, is a risk factor for esophagitis, Barrett’s esophagus (BE), and 
EAC. There are no previous studies assessing risk of inflammation, metaplasia, and 
cancer among adults in relation to perinatal characteristics. 
Aims This thesis aims to explore the effect of gestational age and size at birth, on the 
risk of being diagnosed with esophagitis, BE or EAC later in life. 
Patients and Methods We performed four population-based case-control studies. As 
cases we identified patients with endoscopy verified esophagitis, BE of intestinal 
metaplasia type, and EAC from the Swedish Cancer Register, the Patient Register and 
from two local Barrett Registers. Control individuals were randomly selected from the 
source population, and matched on age, sex and location of birth. We collected 
exposure data from birth records, including the variables gestational age, birth weight 
and length, and maternal diseases, among others. Using conditional logistic regression 
we modeled the risk of being a case based on exposure status, and calculated odds 
ratios (OR) and 95% confidence intervals (CI). A p value of 0.05 was considered 
statistically significant.  
Results Compared to birth at term with adequate birth weight for gestational age, 
preterm birth and being SGA increased the risk of being diagnosed with esophagitis 
(OR 2.7, 95% CI 2.2-3.5 and OR 1.5, 95% CI 1.3-1.7, respectively), and even more so 
among those diagnosed before 10 years of age (OR 6.8, 95% CI 4.7-10.0 and OR 2.0, 
95% CI 1.6-2.5, respectively). We found an increased risk of being diagnosed with BE 
among those born SGA and <3
rd
 percentile (OR 3.0, 95% CI 1.4-6.4), as well as those 
in the 3
rd
 to<10
th
 percentile (OR 1.8, 95% CI 1.0-3.1). The risk of BE was also 
increased among those with a birth weight <2,500 grams (OR 8.2, 95% CI 2.8-23.9). 
The risk of EAC was increased by 13% per week preterm birth, compared to birth at 
term (OR 1.1, 95% CI 1.0-1.3). No effect of size at birth was seen for EAC, or for 
cardia adenocarcinoma and esophageal squamous cell carcinoma. 
Conclusions Altogether, these data indicate that gestational age and size at birth are 
strongly associated with risk of esophagitis and BE later in life. Furthermore, the results 
  
indicate that preterm birth is associated with a risk of EAC and cardia adenocarcinoma, 
but not esophageal squamous cell carcinoma.  
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LIST OF ABBREVIATIONS AND DEFINITIONS 
 
BE Barrett’s esophagus. Specialized, intestinal columnar 
metaplasia in the lower part of the esophagus. 
BMI Body mass index 
CAC Cardia adenocarcinoma 
CI Confidence Interval 
EAC Esophageal adenocarcinoma 
EGD Esophagogastroduodenoscopy. Camera examination of the 
esophagus and stomach. 
Endoscopy Everyday term for EGD 
ESCC Esophageal squamous cell carcinoma 
Esophagitis Inflammation of the esophagus. In this work “esophagitis” 
exclusively denotes erosive esophagitis, ulcerations of the 
esophageal, squamous mucosa caused by GERD. 
GER Gastroesophageal reflux 
GERD Gastroesophageal reflux disease 
Gestational age Age at birth in weeks, from first day of last menstrual period. 
ICD International classification of diseases 
KI Konfidensintervall 
LES Lower esophageal sphincter 
OR Odds Ratio 
PAD Pathological anatomical diagnosis 
PIN Personal identity number (Personnummer) 
Pys Person years, a unit including number of individuals and time.  
SCB Statistiska Centralbyrån 
SGA Small for gestational age. A birth weight less than 2 standard 
deviations below the average for that gestational age. 
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1 INTRODUCTION 
 
This journey started in January 1998 when I worked part time at the Clinical 
Epidemiology Unit to sponsor my season as a ski bum in the French Alps. I assisted in 
collecting birth record data for a cohort of preterm and low birth weight infants. The 
study found an unexpected 7-fold increase in risk of esophageal adenocarcinoma 
(EAC) in this cohort
1
, and generated the hypothesis and research questions that are the 
foundation of this thesis project. Now in 2013, I am proud to present the results of some 
of the choices I made that winter. 
 
The question that was raised was: why would there be an increased risk of EAC among 
individuals that were born preterm? Infants regurgitate frequently during their first year 
in life and preterm infants even more than term born infants. Gastroesophageal reflux in 
adults is a main risk factor for EAC. Is there a possible association, or was it a chance 
finding? 
 
There are different physiological prerequisites in the upper gastrointestinal tract in 
infants compared to adults, the pattern of reflux is different. But infant reflux may in 
some individuals continue into childhood and even adulthood, thus giving this 
individual a prolonged exposure time to the refluxate. Not much is known of how the 
mucosa of the preterm infant handles refluxate, if it can be damaged even by ‘normal’ 
reflux. To address this research question in a more comprehensive fashion, we added 
the biologically relevant pre-stages of EAC to the narrative; erosive esophagitis and 
Barrett’s esophagus (BE), and the plan for a full thesis was formed.  
 
The main aim of this thesis is to elucidate if gestational age at birth or size at birth 
increases the risk of esophagitis, BE and EAC later in life.  
 
 
 2 
2 BACKGROUND 
2.1 EPIDEMIOLOGY OF PRETERM BIRTH AND SGA 
2.1.1 Definitions of age and size at birth 
At birth the infant’s gestational age is calculated in completed weeks, and it is a 
measure of the duration of the pregnancy. Either it is calculated from the date of the 
first day of the last menstrual period, or by an ultrasound examination in early 
pregnancy (since the 1980’s in Sweden)2. A pregnancy lasting 280 days or 40 
completed weeks is the ‘normal’ duration of a pregnancy and a birth in week 37 to 42 is 
considered a term birth (Figure 1). Birth before 37 completed weeks is called preterm 
birth, before 32 weeks is very preterm, and before 28 weeks is extremely preterm
3
. 
 
 
Figure 1 Definitions of gestational age, adapted from Tucker et. al 2004. 
 
Regarding birth weight, WHO has defined low birth weight as less than 2,500 grams 
4
. 
Most infants born preterm are also of low birth weight, but not all of them. By 
combining gestational age and birth weight, size at birth can be estimated. An infant 
can be of lower birth weight than expected for its age and thus be small for gestational 
age (SGA). The concept of SGA was first used in the 1950’s 5, and today it is defined 
as having a birth weight for gestational age less than 2 standard deviations below the 
average weight for gestational age in a reference population, which is approximately 
equivalent to <3
rd
 percentile 
6
. SGA can also be defined as a weight for gestational age 
below the 10
th 
or 5
th
 percentile
7
. In this thesis we defined SGA as being either <3rd or 
<10
th
 percentile of birth weight for gestational age. At the other extreme are infants 
born large for gestational age (>97
th
 percentile), but most infants are born adequate for 
gestational age (AGA)
6
. Ponderal index (PI) is another measure of size sometimes used 
as an indication of asymmetrical weight for length in infants, to judge if an infant is fat 
   3 
or thin. PI is calculated with the formula PI=100*(birth weight/birth length^3), and low 
values may indicate intra-uterine growth restriction of the fetus
8
. 
 
 
Figure 2 Total number of births annually in Sweden 1920-2010. Data from Statistics Sweden. 
 
2.1.2 Incidence and survival 
In Sweden the number of births per year has varied between 85 and 140 thousand since 
1920 (Figure 2). Since the early 1970’s, about 4-5% of the births annually are preterm 
births (Figure 3), and an additional 1% are very preterm births.
2
 Globally the incidence 
of preterm birth varies over time and between countries, from 5-9% in many developed 
countries to almost 12% in the United States 
9
 and 16% in Zimbabwe
10
; the incidence is 
increasing in Brazil 
11
, decreasing since 2006 in the USA 
9
, and have been stable in 
Sweden since the early 1980’s (Figure 3). Neonatal death rates have decreased during 
the past 20 years among all births (figure 3), and especially among those born preterm 
(data not shown)
2
.  
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Figure 3 Annual percentage of births with gestational age <37 weeks and number of neonatal deaths per 1000 
live births. Data from the National Board of Health and Welfare.  
 
There is a scarcity of historical data on rates of preterm birth and neonatal survival, the 
Swedish Board of Health and Welfare only has statistics from 1973 and onward. A 
publication from 1914 states that approximately 1 in 10 Swedish infants died before 1 
years of age, often from nutritional problems
12
. An historical cohort of infants born in 
Sweden 1925 to 1949 found that 3,361 out of approximately 250,000 infants (1.3%) 
were either born before 35 completed weeks of gestation or with a low birth weight 
(2,000 grams for girls or 2,100 grams for boys)
1
. In a study from a Chicago hospital 
following-up preterm and low birth weight infants born 1920 to 1950, approximately 
83% survived to adulthood which is comparable to a death rate of 170 per 1000 live 
births 
13
.  
Neonatal care of the preterm or ‘small’ infant has varied over the years. An active 
approach was advocated from late 19
th
 century to the 1930’s. From the 1940’s to the 
mid 1960’s was a period of well intended but not always successful interventions, 
especially in the USA. The preterm born infants were for example not fed but observed, 
for the first hours or even days of life, which affected both mortality and morbidity in a 
negative way
14, 15
. In Sweden in the 1950’s, infants with a birth weight <2,500 grams 
were considered preterm and dysmature, in need of extra assistance with body 
temperature and feeding. Bottle fed infants were known to have more feeding- and 
gastrointestinal problems
16
. For most infants born after 32 weeks of gestation the 
survival and outcome is and has been almost as good as for infants born at term 
17
, but 
the outcome for male preterm infants is generally worse than for females
18
. 
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2.1.3 Causes of preterm birth and SGA 
Preterm birth is either elective, i.e. medically indicated (about 1/3) or spontaneous 
(about 2/3). The cause of preterm birth, whether induced or spontaneous, is unknown in 
most deliveries, but factors including inflammation or infection, placental ischemia, 
stress and hormones, all play roles in the process. The two most common causes of 
induced preterm birth are the maternal hypertensive disorder pre-eclampsia and intra-
uterine growth restriction (IUGR), a condition of reduced growth velocity of the fetus 
caused by maternal malnutrition and placental malfunctioning
11, 19
. Additional maternal 
risk factors for preterm birth are low maternal age, low socioeconomic status, multiple 
previous pregnancies or preterm delivery, family history of preterm delivery and 
uterine or cervical abnormalities 
20
. 
Among the causes of being born SGA is IUGR one of the most common, and the two 
are sometimes and wrongly interchanged. Additional causes and risk factors for SGA 
are maternal hypertensive disease with or without pre-eclampsia, genetic factors both in 
the mother and the fetus, chromosomal abnormalities like Down syndrome, and 
infections. The single most important risk factor is tobacco smoking, in a dose 
dependent way
7, 21
. 
 
2.1.4 Outcomes of preterm birth and SGA 
A general statement is that the lower the gestational age is, the higher is the risk of 
morbidity and mortality associated with the prematurity
22, 23
. 
The gastrointestinal tract is quite immature until about 30 weeks of gestation, when 
most physiological- , digestive- and functional-parts are in place. Coordination of 
sucking, swallowing and breathing that is necessary for successful oral feeding, is 
possible from 34 weeks of gestational age
24
. Infants born before 35 weeks usually 
require assistance to keep up the homeostasis, i.e. they need help in regulating their 
body temperature, respiration, circulation and nutrition. They need to be fed with 
assistance, for example feeding through a nasogastric tube or parenteral feeding and 
often with supplementation of calories to the recommended feed human breast milk
15, 
25
. It is common for preterm born infants to fail to grow as they would have if still in 
the womb. It is also more common with a late passage of the first meconium, feeding 
intolerance and constipation partly due to formula feeding in this population 
23, 26, 27
. 
The bacterial colonization of the gut in the newborn infant, necessary for maturation of 
the gastrointestinal system and nutrient absorption, is delayed and somewhat abnormal 
 6 
in the preterm infant. This is suggested to affect balance of the gastrointestinal system 
and increase the risk of diseases like necrotizing enterocolitis in this population
28, 29
.  
Medical problems affecting organ systems other than the gastrointestinal tract include 
an increased risk of cerebral hemorrhage leading to brain damages
30
, infections, 
bronco-pulmonary dysplasia
31
 and retinopathy of prematurity that can lead to 
blindness
32
. The long term consequences of prematurity can be of neurological-, 
somatic- and socioeconomic- character. Examples are cerebral palsy, hearing- or visual 
impairments, learning difficulties 
17
, diabetes mellitus, cardiovascular disease including 
hypertension 
33
, and low socioeconomic status 
34
.  
The long term consequences of being born SGA includes an increased risk of 
psychosocial disadvantages and cognitive impairments
7
, hypertension 
33
, ischemic heart 
disease 
35
,  diabetes mellitus type 2 
36
 and short stature if there is no catch-up growth in 
early childhood.  
In conclusion, there are many causes of preterm birth and of SGA birth and the two 
conditions are often, but not always, present in the same infant. As the causes as well as 
the treatments are so differentiated, the resulting population of preterm and SGA 
individuals is heterogeneous. Gestational age at birth affects the health of the infant 
more than size at birth does, both in the short- and the long perspective. The severe 
cases of long-term morbidity caused by prematurity is mainly found in the very preterm 
(<32 weeks) and in the extremely low birth weight groups (<1000 grams), but the 
major part of the morbidity is accounted for by the moderately preterm population (33-
38 weeks) as they are a larger group
34
. It is most likely that the association between 
gestational age at birth and morbidity, is a gradual process
22, 23, 37
, and the majority of 
preterm born individuals do very well when they grow up. 
 
2.2 ANATOMY AND PHYSIOLOGY OF THE ESOPHAGUS 
2.2.1 Anatomy 
The esophagus or the gullet is the organ of interest in this thesis. It is, roughly 
described, the muscular tube linking the mouth to the stomach (Figure 4). At birth it is 
8-10 cm long, it doubles in length during the first years in life and is approximately 25 
cm in adult individuals
38
. The upper third is composed of striated muscle, the lower 2/3 
of smooth muscle and it is enervated by the cranial nerve X, the vagus nerve. The 
esophageal distal ending is located at the level of the diaphragm at birth, and sinks to a 
location approximately 3 cm below the diaphragm after a couple of years 
39
. The entire 
esophagus, from the upper esophageal sphincter to the distal ending at the z-line, is 
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lined with a pale pink stratified, non-keratinized, squamous epithelium (Figure 6 A). 
There is mucus producing glands in the wall of the esophagus, for lubrication that 
facilitates swallowing 
38
. 
In the lower end of the esophagus where it meets the stomach, is the lower esophageal 
sphincter (LES) located. It is a functional area with a higher pressure than in the parts 
of the esophagus above or below, not an anatomical structure. In resting state the 
esophagus is relaxed and collapsed, unlike the open structure in figure 4, and the LES is 
closing the passage between the esophagus and the stomach. 
 
 
Figure 4 Anatomy of the distal esophagus and stomach, by T. Conaglen. 
 
2.2.2 Pathophysiology of reflux 
The LES relaxes to allow passage of food, liquid or air. This transient relaxations of the 
LES is a necessary and ‘normal’ physiological function to let food in and excess air out, 
but at the same time facilitates reflux
40
. Gastroesophageal reflux (GER) represents the 
passage of contents from the stomach backwards up into the esophagus. There are 
many pathophysiological mechanisms causing or worsening GER, including a reduced 
production of saliva, increased number of transient relaxations of the LES, low resting 
pressure of the LES, hiatal hernia, increased intra-abdominal pressure (from overeating, 
 8 
cough or obesity), slower emptying of the stomach or impaired neurological function of 
the esophagus
41
. Not only are the mechanisms of how GER arises important, but also 
what and where. The composition of the refluxing stomach contents (acidic gastric 
juice, digestive enzymes, food items, beverages, gas, or bile and pancreatic juices from 
the duodenum) as well as how high up in the esophagus the reflux reaches, affects the 
influence the reflux has on perceived symptoms and on what damage it can cause
42
.  
 
 
Figure 5. Classification of reflux symptoms according to severity. Modified from Dent et. al. 2005. 
 
2.3 GASTROESOPHAGEAL REFLUX DISEASE IN ADULTS 
The definition of gastroesophageal reflux disease (GERD) has been and still is debated 
and there is no gold standard for the diagnosis
43
. “Gastroesophageal reflux disease is a 
condition which develops when the reflux of stomach contents causes troublesome 
symptoms and/or complications” 44, and it is up to the patient to decide when it is 
“troublesome”. GERD can be interpreted as an umbrella term, including severe 
symptomatic GER and the consequences of it, both esophageal manifestations and 
extra-esophageal manifestations. There is an overlap of the symptoms and signs of 
GERD with other upper gastrointestinal diseases; a patient can present with typical 
GERD symptoms without having visible signs of erosions at endoscopy, and patients 
can have esophagitis and be asymptomatic
43, 45, 46
. With reflux as a common 
denominator there is a likely development from esophagitis via Barrett’s esophagus to 
adenocarcinoma
47
, but the number of patients passing all these steps to EAC is very 
limited
48
. The risk of severe outcomes and complications of GERD increases with 
increasing frequency and duration of the GER, and not necessarily with the severity of 
the symptoms
49
. 
 
2.3.1 Gastroesophageal reflux disease 
GERD is estimated to affect at least 1 in 5 adult individuals in the westernized world, 
and it is in spite of a ‘simple’ appearance a debilitating and costly disease. The major 
Symptoms from 
gastro- 
esophageal 
reflux 
Infrequent or 
mild 
Minor impacts 
Not disease 
(GER) 
Frequent or 
severe 
Significant 
impact 
Reflux disease 
(GERD) 
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symptoms according to ‘The Montreal Definition and Classification of GERD’ are 
heartburn, regurgitation, and retrosternal or epigastric pain
44
. Esophageal complications 
of GERD, which are the diagnoses and outcomes of interest in this thesis, include 
erosive esophagitis, strictures, metaplastic BE and EAC (Figure 6, A-D). Extra-
esophageal manifestations of GERD are chronic cough, chronic laryngitis, dental 
enamel erosions and asthma, among others
50
. GERD leads to a lowered rating of the 
quality of life, comparable to the effect of chronic diseases like diabetes mellitus or 
arthritis
51, 52
. GERD is costly for the affected individual as well as for society, in terms 
of productivity loss at work and prescribed drugs
53, 54
. A recently published study 
showed that approximately 3-4% of all outpatient clinic visits in Sweden, were due to 
GERD
55
. 
Between 14% and 30% of the adult North American and European populations reports 
at least weekly reflux symptoms 
56-59
, and a recently published large population-based 
study from Norway reported a prevalence of up to 40% for any reflux symptoms 
60
. 
There seems to be a geographical gradient in the prevalence of GERD 
40
 and it is less 
prevalent in Asia, where a recent review estimates that 10% of the population suffers 
from GERD 
61
. GERD is most probably a chronic disease with a high prevalence and a 
low incidence
56, 62
, meaning that not very many new patients are diagnosed each year, 
but those who have it are affected for a long time. There are indications of an increasing 
prevalence in most parts of the world during the past 30 years
60, 63
, possibly at least in 
part due to the increasing number of obese people.  
The main known risk factors for GERD are abdominal obesity and high body mass 
index (BMI)
40
, heredity
64-66
, tobacco smoking
40, 67
 and hiatal hernia
50
. There is also an 
association between GERD and low socioeconomic status and being pregnant
68
. It is 
less clear whether overeating, coffee, alcohol or other dietary habits, like spicy food or 
a diet high in fat or low in vegetables, affects the risk of GERD, although these factors 
might evoke occasional episodes of reflux symptoms
40
. GERD is equally common in 
men and women, and it is increasing with age
58, 69
. Among patients with GERD 
examined with endoscopy, it is estimated that 60% have no signs of inflammation, i.e. 
non-erosive GERD, 30% have esophagitis and 10% have BE
48
. 
 
2.3.2 Esophagitis 
Erosive esophagitis is the most common complication of GERD. Esophagitis, i.e. 
inflammation of the esophagus, can be of various types and origins; erosive esophagitis 
caused by GERD
50
, eosinophilic esophagitis due to food allergy and/or atopy
70
, 
 10 
infectious or fungal esophagitis for example caused by Candida species, or erosive due 
to ingestion of lye or other corrosive agent
71
. Hereafter in this thesis the term 
“esophagitis” denotes exclusively erosive esophagitis caused by GERD (Figure 6A). 
Esophagitis is found in 11-15% of the general adult western population, and in 
approximately 25% of those reporting GERD symptoms
59, 72
. Among those diagnosed 
with esophagitis, 1 to 2 out of 3 individuals report having any reflux symptoms, and 
many esophagitis patients are thus asymptomatic
73
. 
Esophagitis is detected by endoscopy and is classified using the Los Angeles 
Classification system, in grades A to D depending on the length and circumference of 
the mucosal breaks
74. A mucosal break is defined as “an area of slough or erythema 
with a sharp line of demarcation from the adjacent normal mucosa…”43, 75 (Figure 6 A). 
 
 
Figure 6 Endoscopic pictures of the esophagus, clockwise from top left. A: arrow heads show areas of erosive 
esophagitis surrounded by normal squamous epithelium; B arrow heads show a peptic stricture; C stars show 
areas of Barrett’s esophagus; D star show adenocarcinoma. Pictures adapted with permission from P. 
Kahrilas, 2008. 
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2.3.3 Barrett’s esophagus 
Another complication of GERD is BE named after Norman Barrett, a surgeon working 
in London in the 1950’s and who identified a “short esophagus”. BE represents a 
metaplastic columnar mucosa replacing the native stratified squamous mucosa of the 
distal esophagus 
76, 77
(Figure 6 C), where metaplasia is the process of one mature cell 
type being replaced by another mature cell type. BE most likely develops as a 
protective response, i.e. the esophagitis heals through a metaplastic process with a cell 
type more resilient to the refluxate
78-80
. There are three histologic types of metaplasia 
where specialized columnar metaplasia of intestinal type, also called type 3, is the only 
type regarded as premalignant, with a potential to transform into adenocarcinoma
81
. 
Hereafter in this thesis ‘BE’ denotes specialized intestinal metaplasia i.e. BE type 3.  
There is a variation in the reported population prevalence of BE due to differences in 
indications and frequency of endoscopy, as well as varying diagnostic criteria and study 
populations in different studies
82
. A large population based study with endoscopy 
findings from healthy volunteers randomly sampled from the Swedish population, 
found BE in 1.6% of the adult general population
83
. It is found in 2.4% of primary care 
patients with dyspepsia 
84
, in 6.8% of a population referred for a colonoscopy 
85
 and in 
about 5-10% of those with severe reflux symptoms 
78, 86, 87
 of which an estimated 3-5% 
have long segment BE and 10-15% have short segment BE 
79, 88
.  
Major risk factors for BE are severe GER of long duration and frequent eruptions, 
esophagitis, hiatal hernia, male gender, obesity and abdominal fat, old age and 
Caucasian ethnicity. Tobacco smoking and hereditary factors are also suggested to 
increase the risk of BE
49
. Alcohol consumption is not proven to be a risk factor, while 
infection with Helicobacter pylori (the gastric ulcer bug), consumption of non steroid 
anti-inflammatory drugs (NSAID’s), wine consumption as well as “healthy” diets rich 
in vegetables and fruit are suggested as protective factors 
49
.  
At endoscopy, BE is diagnosed by visible changes of the mucosa and is confirmed by 
histological examination of biopsy specimens showing intestinal metaplasia. In 1998 
BE was suggested to be classified and described as either long segment BE (≥3 cm) or 
short segment BE (<3 cm) but the clinical importance of this classification is debated
79, 
89. In 2006 an international working group presented the ‘Prague C & M Criteria’ for 
grading of circumference and maximal height of the BE lesions
90
. The histopathology 
of BE can be classified as non-dysplastic, low-grade dysplasia or high-grade dysplasia, 
where high-grade dysplasia has the highest potential to become malignant
79
.  
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2.3.4 Esophageal adenocarcinoma 
Esophageal cancer is among the top-10 most common cancers 
91, 92
, and accounts for 
almost 6% of all cancer deaths globally 
93
. There are two histologic types of esophageal 
cancer, squamous cell carcinoma and adenocarcinoma (Figure 6D). They differ in their 
etiology, but share methods of diagnosis, treatment and prognosis. 
The symptoms of EAC are initially GERD symptoms, and later in the process 
dysphagia, odynophagia (difficulties and pain at swallowing, respectively) and weight 
loss can appear. The tumor grows in an infiltrative and ‘patchy’ way, it metastasizes 
early and most patients seek help at a late stage, which influences the prognosis and 
results in a poor 5-year survival rate
81, 94
. From the 1950’s until 2008 the 5-year 
survival rate has increased from 3-4% to almost 16%, which still is clearly lower than 
almost all other tumor types
94-96
. Before the 1970’s EAC was rare but has since the late 
1980’s increased in incidence, especially in the developed world in a drastic way. For 
example, the incidence in the white male American population 1974-1976 was 
0.7/10
5
/person years (pys), for the period 1992-1994 it was 3.2/10
5
/pys
97
, and increased 
to 5.69/10
5
/pys in 2000-2004
98
. In Denmark 1970 to 1991 the age- and sex-adjusted 
incidence rose from 0.3/10
5
/pys to 2.3/10
5
/pys
99
. The actual number of affected patients 
is low compared to other tumors like breast cancer (135/10
5
/pys in USA) or lung cancer 
in American men (85/10
5
/pys), but the increase is high
94
. What causes the increase, as 
well as the geographical gradient of it, remains unexplained 
100
. Nowadays EAC is the 
most common type of esophageal cancer in many countries in the developed world 
93
. 
In Sweden there were 210 new cases of EAC in 2010 (Figure 7). 
 
 
Figure 7 Number of cases of EAC per year in Sweden 1970-2010. Data from the National Board of Health and 
Welfare. 
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EAC is most common in developed countries with a westernized lifestyle, and the 
typical patient is a male of Caucasian origin, 65 years of age or older and with a long 
history of GERD. Like most types of cancer EAC is a multifactorial disease, but there 
are a number of known risk factors like gastroesophageal reflux disease 
101
 with or 
without hiatal hernia 
102
, BE 
47, 99
, high BMI 
103
and more specifically abdominal obesity 
104
and low socioeconomic status 
105
. Tobacco smoking is a moderate risk factor for 
EAC, while alcohol consumption does not contribute to the etiology of this tumor
106, 
107
. Low dietary intake of fruit and vegetables is followed by an increased risk of EAC, 
while other dietary factors like intake of fat and meat have been studied but without 
conclusive results 
93
. The male predominance estimated to be 4-9:1 is unexplained 
100
, 
and studies of the effects of estrogen exposure have not given answers as to why there 
is such an imbalance 
108-110
. Breastfeeding has however recently been established as a 
protective factor in women
111
. Infection with Helicobacter pylori has been reported to 
be a protective factor
112, 113
. Nowadays populations of developed countries are infected 
to a much lesser extent than earlier and also compared to less developed countries, 
which is reflected in lowered rates of cancer in the stomach
94
. By which mechanism the 
protection by H. pylori works remains to be elucidated
113
. 
Although less than 5% of EAC patients were previously diagnosed with BE
99, 114
, BE 
increases the risk of EAC 30 to 125 times compared to a very low risk in the general 
population (Figure 7) 
115, 116
. A meta-analysis combining the results from 51 studies 
estimate the incidence of EAC in BE patients being 6/1000/pys of follow up (95% CI 
4.7-8.4/1000 pys), equal to a rate of transition in 0.6% annually
116
. Other, smaller 
studies estimated this number to be as high as 3.5% annually
117, 118
, or 6% if there is 
high-grade dysplasia present
115
. BE transforms to EAC twice as often in men than in 
women, something that is reflected in the skewed male to female ratio of EAC
119
. The 
incidence of BE appears to be rising, and this is suggested to partially explain the rising 
incidence of EAC
120-122
. Up to 40% of EAC patients claim they never experienced 
GERD symptoms
101
.  
 
2.4 GASTROESOPHAGEAL REFLUX DISEASE IN INFANTS AND 
CHILDREN 
2.4.1 In infants 
It is a known phenomenon that infants regurgitate and throw up. Infant GER is 
commonly considered effortless, and it is usually classified as physiological. It is 
considered pathological only when associated with severe symptoms or complications. 
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In infants as well as in adults described above, is it when the LES relaxes that gastric 
content can enter the esophagus
123
. Infants have differences in the anatomy as 
compared to adults, increasing the likelihood of GER. Their esophagus is shorter, the 
area of the LES is smaller and it is not located below the diaphragm, which reduces the 
efficiency of the sphincter
39, 124
. Furthermore, they ingest fluids equivalent to 14 
liters/24 h for an adult and they have a slumped sitting position or are laying down
125, 
126
. Infants have the same enzymatic composition and pH in the stomach as adults, pH 
drops to <2 within hours of birth for infants as young as 24 weeks
125, 127, 128
. It is likely 
the acidity of the refluxate that defines the symptoms
123, 126
.  
Physiologic GER is found in almost all infants before 3 months of age, in 40-65% of 
healthy infants before one year of age and is outgrown by 18 months of age in most 
infants
125, 129
. Pediatric gastroenterologists distinguish the otherwise healthy ‘happy 
spitter’ from infants with GERD. It is known that infant GERD can lead to feeding 
problems in early childhood
130
, but not much is known of the long term consequences 
of infant GERD. 
Symptoms of GERD in infants include inadequate weight gain or even weight loss, 
crying, irritability or arching backwards during or after feeding or excessive 
vomiting
124
. It has been suggested that GERD causes extra-esophageal consequences 
like apnea and respiratory diseases, but the evidence are conflicting
131
. 
It is estimated that 1 in 300 infants have GERD 
132
 and that 6-7% of infants come to 
medical attention during their first year in life because of GERD 
125
. Risk factors 
include use of nasogastric feeding tubes 
133
, very low birth weight 
125
, neurological 
impairments, esophageal malformations 
132
, exposure to tobacco smoke 
124
 and preterm 
birth 
134, 135
. In preterm born infants three factors may add to the risk of GERD; the 
hypotonic state of their muscles, a reduced oropharyngeal capacity of clearance of 
refluxate and a lack of peristaltic movements to clear refluxate from the esophagus 
125, 
136
. In general, the smaller or more premature the infant is and the more complicating 
factors or diseases there are, the bigger is the risk of infant GERD
134, 137, 138
. 
 
2.4.2 In children 
Older children also have GERD. The prevalence ranges from 2% to 20% in otherwise 
healthy children
139, 140
, and possibly up to 27% in former preterm children
141
.  
Children can have esophagitis and BE as well, but the true prevalence is unknown. It is 
most likely lower than in the adult population
142
, but the definitions have varied over 
time and between studies
142, 143
. There are even some rare cases of EAC described in 
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children
144
. The prevalence of esophagitis in the general pediatric population is 
estimated to be 0.5-5%
38, 145, 146
, and 40-83% in children with GERD 
147-149
.  
The prevalence of BE in the general pediatric population is estimated to be <0.02%
150
, 
0.12-4.8% in children with GERD
140, 151
, and the incidence is possibly rising
152
. 
 In conclusion, the pathophysiological consequences of infant GER is debated
126
, and 
the long term effects of infant or childhood GER are not known
129
. GERD is most 
likely a chronic disease with childhood onset that wax and wane over the years, and 
that continues into adulthood
125, 153-155
. 
 
 
2.5 CLINICAL ASPECTS OF GERD 
2.5.1 Histopathology of GERD 
2.5.1.1 Inflammation to metaplasia 
 The transition from esophagitis to EAC progresses via a ‘metaplasia-dysplasia-
carcinoma’ process, and chronic GER is the driving force in the development47. The 
histopathological signs of inflammation are elongated vascular papillae in the mucosa, 
increased height of the growth zone, basal cell hyperplasia, dilated intercellular spaces 
and infiltrating immunological cells
48
. The chronic inflammation releases a number of 
inflammatory mediators, which causes cell transformation through different 
mechanisms
47
. 
 Esophagitis and erosions heal with the original squamous cell type in most cases, and it 
is not known why the erosion heal with metaplastic columnar cells i.e. BE in some 
individuals. The progenitor cell of BE is not know and it is hypothesized that stem cells 
in the basal layers of the esophageal mucosa are involved. When the stem cell become 
exposed to refluxate and chronic inflammation a transforming process starts, resulting 
in the metaplastic change of cell type to a type more adapted to refluxate 
82, 156-159
.  
 
2.5.1.2 Dysplasia to cancer 
With continuing inflammation and reflux, some or at least one metaplastic BE cell 
continue to develop mutations, and becomes dysplastic. Whether the length or grade of 
dysplasia is important is debated, and it is almost impossible to predict the speed of this 
transition and in whom it will take place
160
.  
There are a number of important mutations in the development from dysplastic BE to 
EAC, but the exact pathway is not known
161
. First the cell cycle regulating gene p16 is 
damaged, followed by an upregulation of cyclin D1 and E, which triggers a state of 
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growth autonomy in the cell. By additional damage to the p53 gene the cell does not 
respond to stop signals nor induce apoptosis, and the cell continues its journey towards 
immortality. These factors, together with growth self-sufficiency, the ability of 
angiogenesis and ability to metastasize, are the hallmarks of a cancer cell
162, 163
.  
No biomarker is found that can predict the progression from metaplasia to dysplasia 
and cancer, and high-grade dysplasia is the best ‘warning sign’ of this process there is 
today
47, 164
.  
 
2.5.2 Diagnostic tools 
A person experiencing symptoms from the upper gastrointestinal tract, like reflux, 
heartburn or pain when swallowing, most probably makes an appointment with a 
doctor. The doctor evaluates the symptoms in the light of the medical history of the 
patient, taking into account risk factors, a clinical examination and perhaps also some 
laboratory tests. Unless the patient presents with alarm symptoms (bloody stool or 
vomiting, weight loss, severe pain) indicating a severe disease and possibly cancer, the 
most common start for the help seeking patient is the ‘test-and-treat’ strategy. 
Treatment with an antacid medication is evaluated after a couple of weeks; symptom 
relief gives the diagnosis GERD ex juvantibus. Questionnaires quantifying symptoms 
or quality of life are valuable tools, and are also used in children
165
. The symptom 
based diagnosis have a sensitivity and specificity of 65-70%
46, 166, 167
. 
To add objectivity to the diagnostic process, an esophagogastroduodenoscopy (EGD) 
can be performed. During this camera examination of the esophagus, stomach and 
duodenum, signs of inflammation, erosions, hernias or cancer can be visualized and 
biopsies taken. The number of biopsies, the method used and the pattern of where they 
are taken depends on what the mucosal lesions looks like and the suspected diagnosis
81, 
168-170
. The final diagnosis is most often made on the basis of the histopathology. EGD 
is a method of high specificity and low sensitivity as many of the patients with GERD 
have no visible erosions
59, 171
.  
With no erosions to examine histopathologically, esophageal impedance monitoring 
visualizing abnormal patterns of peristalsis in the esophagus, or a pH monitoring can be 
performed. The impedance measurement is thought to be more informative than the 
mere pH measurement
172, 173
.  
When EAC is diagnosed an esophageal ultrasound can be used to examine the 
invasiveness or depth of the tumor, and a PET-CT examination (a combination of a 
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computer tomography and a positron emission tomography with radioactivity labeled 
molecule) to search for metastases. 
 
2.5.3 Treatment of GERD in adults 
The initial treatment for GERD is lifestyle changes like weight loss, smoking cessation 
or avoidance of certain foods; the level of evidence for this is low 
174
. The next step is 
antacid drugs, substances that either neutralizes the acidity of the stomach or prevents 
acid secretion and thus reduces the symptoms. Examples are proton pump inhibitors 
(PPI’s), histamine-2 receptor antagonists (H2RA) and buffering salts. The effect of 
PPI’s on symptom relief, healing of esophagitis and on rated quality of life is better 
than what is reported for H2-blockers 
174
. In severe cases where antacids do not give 
enough symptom relief, surgery is an option. The procedure called fundoplication has 
been performed since the 1950’s, and has a well documented effect on symptoms174.  
BE lesions can either be ablated or resected, the latter technique allows further 
histopathological examination of the lesion
170
. There is a variety of ablative techniques 
all aimed at destruction of the tissue by adding energy; the method used depends on the 
traditions and experiences at the clinic, and on the condition and state of the patient. 
After ablation and together with PPI treatment, the mucosa can heal and regenerate 
native squamous cells
170
. 
‘Buried metaplasia’ is a debated concept after ablation of BE, where some metaplastic 
cells survive under the healing layer of squamous cells and these cells might continue 
to transform without being readily detected
82
. For this reason there is an ongoing debate 
whether doctors should “wait or ablate” if they find a BE in a patient, and the existing 
guidelines on the topic differ between countries
116, 170, 175
. Yet, no treatment of BE has 
proved to reduce the rate of transition to, or mortality from EAC
115, 161
. Screening for 
BE in patients with GERD is not recommended; but once BE is detected, surveillance 
is recommended depending on histopathology. 
The treatment of EAC consists of neoadjuvant chemo- and/or radiotherapy and 
surgery
81
. There is no evidence that aggressive anti reflux therapy in early GERD 
stages, later reduces the number of deaths from EAC
79
. 
 
2.5.4 Treatment of GERD in children 
Treatment of GERD in infants and children is similar to what is described above for 
adults
143, 176
. The ‘test-and-treat’ strategy is most commonly used177. Unlike the adult 
recommendations, there are a number of lifestyle changes proven to result in less 
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troublesome reflux, namely to thicken the feed, rule out cow milk allergy and to let the 
infant rest in a prone or right lateral position after feeding 
178, 179. PPI’s are used in 
infants, in spite of the fact that no PPI substance has been approved in this 
population
176
. In children that do not respond to medical treatment, fundoplication is an 
option
180
.  
 
   19 
3 AIMS AND OBJECTIVES 
Due to a development in the care of pregnant women and their offspring, the number of 
preterm born and SGA infants surviving to adulthood is increasing. Preterm born 
infants have more GER than infants born at term, possibly prolonging the exposure of 
their esophagus to refluxate. Not much is known of the effects of preterm or SGA birth 
on gastrointestinal health later in life. Symptomatic reflux is a common complaint in 
many populations among adults as well as among children, and GERD is most likely a 
chronic disease with childhood onset. GERD is a risk factor for esophagitis, BE and 
EAC, where EAC is a deadly tumor type with an unexplained and rapid increase in 
incidence. In a hypothesis generating study, an increased risk of EAC was found in a 
cohort of infants born preterm and with low birth weight. Therefore, our aim with this 
thesis project is to answer the following questions: 
 
1) Is gestational age or size at birth associated with an increased risk of 
esophagitis later in life? 
 
2) Is gestational age or size at birth associated with an increased risk of BE later 
in life? 
 
3) Is gestational age or size at birth associated with an increased risk of EAC 
later in life? 
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4 MATERIALS AND METHODS 
All four studies in this thesis are population based case-control studies. For each study 
we chose a group of individuals with a pre-defined outcome, a diagnosis of interest; 
these individuals were the cases. We collected information on the exposure from the 
birth records at different hospitals, or from a register. We chose the control individuals 
for each case in a pre-defined manner, collected their exposure data and finally made 
sure that they were alive at the date of the respective cases diagnosis. Sweden is a 
country with a long and robust tradition of archiving, and has excellent sources of data 
for epidemiological research. 
 
4.1 METHODOLOGICAL CONSIDERATIONS 
4.1.1 Case-control design 
The case-control design has been a part of the epidemiological toolbox since the 1950’s 
and it was initially developed for etiologic studies of cancer. Its validity has been and is 
debated as it is a method that requires careful handling, in spite of its simple and 
straightforward appearance. The case-control design has been developed and improved 
over the years, and it is now a method used in diagnostic and prognostic as well as 
etiologic research 
181
. With a case-control design it is possible to study multiple 
exposure variables, it is useful for rare outcomes and for situations where there is a long 
latency between exposure and outcome. It is also an efficient study design both in terms 
of time and money
181
.  
 
4.1.2 Control selection and matching in case-control studies 
The control group is selected to represent the non-diseased part of the source 
population. Ideally the controls are a random sample from the source population so that 
their likelihood of becoming a control does not depend on their exposure status. We 
selected controls at the same point in time as the cases (density sampling)
182, 183
.  
Matching is a method of balancing cases and controls with respect to certain 
characteristics. For example, in a study with a male dominance among the cases, 
randomly chosen controls will probably not reflect this skewed sex distribution, but be 
normally distributed (50% males, 50% females). This results in male cases without 
male controls and an abundance of female controls. Matching handles the imbalance 
and increases the efficiency and statistical power of the study. Matching on a variable 
makes it impossible to assess it as an explanatory variable, because the proportion of 
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exposed is set by the design.
183
. In our studies we matched on sex and age due to a 
known skewed distribution of these factors for the outcomes of interest. We also 
matched for location of birth for practical reasons, and it might hypothetically have lead 
to an equal distribution of some background exposures.  
 
4.1.3 Follow-up of controls 
Having identified all the cases and controls and their exposure data, what was left was 
to make sure the controls were alive at the time of their respective cases diagnosis. If 
not, the prerequisites stated above are not valid. From a place of birth, a mother’s name 
and perhaps a name of the newborn control individual, we traced the individuals 
through parish archives and the Register of the Total Population. The fastest way to do 
this is by using the micro film copies of all parish books located in the depot of the 
National Archive in Arninge, Stockholm, and the web page Ratsit.com which contains 
selected but sufficient data from the Register of the Total Population. 
 
4.2 DATA SOURCES FOR COLLECTING CASES AND CONTROLS 
The personal identity number (PIN) is assigned to all Swedish citizens at birth or 
immigration since 1947. The PIN is a unique 10 digit identifier used in most contacts 
with the health care system and authorities. By using the PIN we were able to retrieve 
archived medical records and link information from the different archives. The PIN is a 
valid identifier, less than 0.5% of assigned PIN’s have been subject to change over the 
years
184
.  
 
4.2.1 The Cancer Register 
From the Cancer Register we identified the cases included in studies I and IV. Initiated 
in 1958, this register contains data on all incident cancer cases in Sweden, by 
histological type, location and stage. Clinicians, pathologists and cytologists must by 
law report findings to the regional oncologic registers, which in turn reports to the 
National Cancer Register. Due to its robust and mandatory reporting system, it is 98% 
complete regarding esophageal cancer
109
. 
 
4.2.2 The Swedish Patient Register 
From the Patient Register we identified the cases included in study II. The register is 
organized using the PIN, and contains data on hospitalizations, diagnosis at discharge 
and surgical procedures. The register was initiated in 1964 by the National Board of 
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Health and Welfare, a governmental agency within the Ministry of Health and Social 
affairs, and has nationwide coverage since 1987. Since 2001 are hospital outpatient 
visits included as well
185
. Diagnoses are coded using the International Classification 
of Disease (ICD) version 8 in 1969 to1986, ICD-9 in 1987 to 1996 and ICD-10 from 
1997 and onward. Surgical procedures are coded using the Swedish versions of the 
NOMESCO Classification of Surgical Procedures version 1.9, ‘Surgical procedures 
6
th
 ed.’ in 1963 to 1996 and ‘Classification of surgical procedures 1997’ from 1997 
and onwards.  
  
4.2.3 The Barrett registers 
The cases to study III were retrieved from two local Barrett’s registers at Ersta Hospital 
Stockholm and Kalmar County Hospital. The registers contain name, PIN, BE segment 
length and year of diagnosis for the patients. 
 
4.2.4 The Register of the Total Population 
This register provided us with information on the cases parents name and birth date, 
and name and correct identity of the controls at follow-up. The Register of the Total 
Population is part of the official statistical body of the Swedish population. Organized 
around the PIN, it contains demographic information on place of birth, sex, age, civil 
status, date of migration or immigration and death, among other things. It is kept by 
Statistics Sweden (Statistiska Centralbyrån, SCB) and is continuously updated by the 
local tax authorities of the National Tax Agency, and finally to SCB. From this register 
we obtained information regarding the place of birth of the cases (births until 1947) or 
the place of maternal residency at time of birth (from 1948 and onward), the name of 
the mother and father of the case and their date of birth. We also used it to trace the 
control individuals. Larger sets of data are accessible with an ethical permit and by file, 
or you can access the data one individual at a time by phone or on the web. With this 
information the next step was to search for information regarding the actual location of 
the birth; only individuals born in hospitals have a traceable birth record, and this was 
done at the parishes. 
 
4.2.5 The Parish registers 
The information we gathered from these registers was location of birth for cases, and 
identity of controls at follow-up. The Swedish parishes have since the 17
th
 century been 
obliged to keep records of all births, marriages and deaths within their population, 
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among other variables. These registers were not only used by the church, but also as a 
means for the state to keep census of the population and enroll soldiers for the army
184
. 
The predecessor of Statistics Sweden was created by a decision by King Fredrik 1
st
  in 
1749
186
. In 1991 the responsibility for the information in these population registers was 
taken over by the tax authorities, resulting in the Register of the Total Population. The 
original parish books are no longer kept at the parishes, but in the eight Regional state 
archives (Landsarkiv) where they are accessible to the public in their original format, 
on microfilm or as scanned computerized copies. Based on the place of birth, we 
searched the books in the corresponding parish until finding the ‘right’ mother and her 
offspring.  
 
4.2.6 The Medical Birth Register 
The Medical Birth Register contains information from delivery wards on almost all live 
births in Sweden since 1973
2
, and was our source of controls to study II. The selection 
of variables in the register has been updated several times since the start. It contains 
information about maternal variables such as age, parity and civil status; birth 
characteristics such as mode of delivery; and child characteristics such as birth weight, 
gestational age and diseases in the neonatal period. The register is kept by the National 
Board of Health and Welfare. 
 
4.3 STUDY POPULATIONS 
4.3.1 Study I and IV 
By combining the pathological anatomical diagnosis (PAD) code of the 
histopathological type of cancer, with the ICD code indicating the location of the 
tumor, we could extract exact eligible cases from the Cancer Register. We collected all 
incident cases of esophageal adenocarcinoma (PAD 094, 096; ICD-9 150), cardia 
adenocarcinoma (PAD 094, 096; ICD-9 151.0) and esophageal squamous cell 
carcinoma (PAD 144, 146; ICD-9 150) diagnosed 1994 to 1997 for inclusion in study I, 
and those diagnosed 1998 to 2004 for study II. Controls were chosen as the three live 
born infants of the same sex, following the delivery of the case at the same maternity 
ward. Twins and infants with severe congenital malformations were excluded. The 
study base was individuals born in hospitals all over Sweden 1912 to 1985, and that 
were alive in Sweden in 2004.  
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4.3.2 Study II 
Everyone in the Patient Register diagnosed with esophagitis (ICD-8 and -9: 530B, -C 
and 530.94; ICD-10: K20 and K21.0) after an endoscopic examination (Surgical 
Procedures 6
th
 edition 288, 448; Surgical Procedures 1997 edition UJC02, UJC05, 
UJC12, UJC15, UJD02, UJD05), and who had retrievable birth data from the Medical 
Birth Register were included as cases. 5 controls per case were selected from the 
Medical Birth Register, of the same sex and age and born in the same county. This 
study was a case-control study, nested within the population of everyone born in 
Sweden and included in the Medical Birth Register from 1973 and onward. The data set 
was provided by the National Board of Health and Welfare. 
 
4.3.3 Study III 
Any patient with GERD symptoms referred to Ersta Hospital, Stockholm 1992-2007 or 
to Kalmar County Hospital 1986-2006, and who following an EGD with biopsies was 
diagnosed with specialized, intestinal metaplasia was included in the register. Of all 
registered cases of BE, only those who had a retrievable birth record were eligible as 
cases in our study. Controls were chosen as in study I and IV. The study population was 
born between 1921 and 1983 in hospitals all over Sweden, but mainly in the greater 
Stockholm region and Kalmar County. 
 
 
4.4 STATISTICAL CONSIDERATIONS 
4.4.1 Statistical models 
We used conditional logistic regression models to calculate odds ratios (OR) as the 
measure of effect with 95% confidence intervals (CI). In study IV we additionally used 
a non-linear polynomial modeling approach, a spline, to allow the data to depart from a 
non-linear relation. With multiple logistic regression one can model the relationship 
between a dependent variable ‘x’ and one or more explanatory variables ‘y1’, ’y2’, ‘y3’ 
etc., and thereby adjust for confounding factors. This means that we built the statistical 
models including the variables in our a priori hypothesis, as well as some potential 
confounding factors. Our models had to be conditional logistic models, due to the 
matching of cases and controls. All data was analyzed using Stata IC11 or Stata IC12, 
Stata Corp, College Station, Texas, USA. 
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4.4.2 Interaction and effect-measure modification 
Interaction is present when the effect measure (in this thesis OR) of one variable, varies 
across values or strata of another explanatory variable. Biological interaction occurs 
when two factors are part of the same causal pathway to disease. In practice such 
interaction becomes evident when the joint effect of two factors deviates from what 
would be expected under the assumption of no interaction. The judgment on interaction 
is dependent on whether the scale is additive or multiplicative. Using logistic regression 
models like we did throughout this thesis, implies that any statistical test of 
homogeneity evaluates deviation from the multiplicative scale. For example; no 
difference in OR between two strata, meaning no effect-measure modification on the 
multiplicative scale, implies a heterogeneity of risk differences on the additive scale
183, 
187, 188
.  
We examined statistical interaction by stratification and by introducing an interaction 
term (z1*z3) into the regression models. We decided which variables to stratify for a 
priori based on biologic reasoning and plausibility
181
.  
In study I we examined potential interaction between gestational age and age at 
diagnosis, hypothesizing that the effect of neonatal factors might be stronger earlier in 
life. In study II we stratified by age at diagnosis for the same reason as in study I, and 
also by sex thinking there might be a difference between the sexes. We also examined 
interaction between gestational age and SGA. In study III we stratified by BE segment 
length for explorative reasons. In studies I and IV we stratified the analysis by the 3 
tumor types knowing that they have different locations, etiologies and risk factors.   
 
 
4.5 ETHICAL CONSIDERATIONS 
We had ethical permits for all four studies from the Regional Ethical Review Board, 
Stockholm. Medical records and information in parish archives younger than 75 years 
is protected by secrecy and we had additional permits from the archives and registers 
that were used for data collection, to access the data. 
In none of our studies did we have informed consent from the study participants. In our 
applications for ethical permits we argued that any breach on the personal integrity that 
comes from medical record- and data handling and subsequent analysis is small, 
smaller than it would be to locate all study participants and inform them about our 
hypotheses and request for their consent to collect the data. Moreover, a majority of the 
case patients of esophageal cancer were deceased at the time of the studies. All data 
 26 
was de-identified after the initial identification and data collection. Data was analyzed 
and presented on group level and it was thus impossible to trace information back to 
single individuals. We believe that the value of our results is of greater good, than the 
potential harm we have done by collecting data from medical records of unknowing 
individuals.   
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5 RESULTS 
This is a summary of the results. For a complete presentation, please see the individual 
studies at the end of the thesis. 
 
5.1 GESTATIONAL AGE AND SIZE AT BIRTH AND RISK OF 
ESOPHAGITIS (STUDY II) 
Of the 7,358 cases and the 34,094 controls included in study II, there was an 
overrepresentation of preterm birth, low birth weight or SGA among the cases.  Being 
born very preterm (≤32 completed weeks) as compared to being born at term, increased 
the risk of esophagitis later in life almost 3-fold (OR 2.7, 95% CI 2.2-3.5), irrespective 
of age at diagnosis. When we stratified by age at diagnosis (Table 1) and sex (data not 
shown), different risk patterns appeared. The risk was highest among those diagnosed 
before 10 years of age and being born very preterm (Table 1). Being born very preterm 
and male gave an almost 10-fold risk increase (OR 9.9, 95% CI 5.9-16.5) in those 
diagnosed before 10 years of age, compared to being born very preterm and female 
which gave a 3-fold risk increase (OR 3.4, 95% CI 1.8-6.4).   
 
Table 1 Gestational age and birth weight for gestational age and risk of 
esophagitis at different ages. 
 
Age at diagnosis of esophagitis 
  OR* (95 % CI) 
 
≤ 9 years 10–19 years ≥ 20 years 
Number of cases/controls 1,907/8,808 1,587/7,138 3,759/17,029 
Gestational age 
   ≤32 weeks 6.8 (4.7–10.0) 2.1 (1.2–3.7) 1.0 (0.6–1.6) 
33–36 weeks 1.8 (1.4–2.1) 1.4 (1.1–1.8) 1.1 (0.9–1.3) 
37–41 weeks 1.0 (referent) 1.0 (referent) 1.0 (referent) 
≥42 weeks 1.1 (0.9-1.3) 1.3 (1.0–1.5) 0.9 (0.8–1.1) 
    Birth weight for gestational age 
  SGA 2.0 (1.6–2.5) 1.5 (1.1–1.9) 1.3 (1.1–1.5) 
AGA 1 (referent) 1 (referent) 1 (referent) 
LGA 1.1 (0.8–1.4) 1.0 (0.8–1.4) 0.8 (0.6–1.0) 
*Model includes gestational age, birth weight for gestational age, maternal age 
and birth order. 
AGA, adequate for gestational age; LGA, large for gestational age. 
 
Being born SGA as compared to adequate for gestational age (AGA) was associated 
with a risk increase of 50% independently of age at diagnosis (OR 1.5, 95% CI 1.3-
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1.7). The effect of SGA was stronger among those diagnosed before 10 years of age, as 
compared to older ages at diagnosis (Table 1). Among those diagnosed before 10 years 
of age the effect of SGA was stronger among females than males. 
The combination of being born preterm and SGA was associated with an OR of 7.4 
(95% CI 4.0-13.9), but we found no statistically significant interaction between the two 
variables (p for homogeneity of ORs = 0.13).  
Neither maternal smoking nor BMI in early pregnancy or the family’s socioeconomic 
status confounded the risk estimates. 
 
5.2 GESTATIONAL AGE AND SIZE AT BIRTH AND RISK OF BE (STUDY 
III) 
Among 331 cases and 852 controls, the male to female ratio was 2.3 to 1. Being born 
with a birth weight of less than 2500 grams, as compared to a ‘normal’ birth weight of 
3000-3999 grams, was associated with an 8-fold risk increase (OR 8.2, 95% CI 2.8-
23.9) (Table 2). 
Table 2 Odds ratios for the diagnosis of BE and birth weight, gestational age 
and a combination of the two.  
  
Number 
cases/controls 
Crude OR  
(95% CI) 
Adjustedᶲ OR 
(95% CI) 
Birth weight 
   <2500 grams 16/12 4.4 (1.9–10.1) 8.2 (2.8–23.9) 
2500–2999 grams 40/93 1.1 (0.8–1.7) 1.4 (0.9–2.2) 
3000–3999 grams 222/594 1.0 (referent) 1.0 (referent) 
≥4000 grams 53/153 0.9 (0.7–1.3) 0.9 (0.6–1.4) 
Gestational age† 
  <37 weeks 19/44 1.2 (0.7–2.2) 1.2 (0.7–2.3) 
37–41 weeks 265/687 1.0 (referent) 1.0 (referent) 
≥42 weeks 39/103 1.0 (0.7–1.5) 0.9 (0.5–1.4) 
Birth weight for gestational age 
  <3d  percentile 16/20 2.5 (1.2–5.0) 3.0 (1.4–6.4) 
3rd to <10th percentile 29/52 1.5 (0.9–2.5) 1.8 (1.0–3.1) 
10th to <25th  percentile 47/118 1.1 (0.8–1.7) 1.3 (0.9–2.0) 
25th to 75th  percentile 150/413 1.0 (referent) 1.0 (referent) 
>75th to 90th  percentile 51/116 1.2 (0.8–1.7) 1.1 (0.7–1.8) 
>90th to 97th  percentile 15/83 0.5 (0.3–0.9) 0.5 (0.3–1.0) 
>97th  percentile 15/31 1.4 (0.7–2.7) 1.6 (0.8–3.4) 
ᶲ Model including birth weight or birth weight for gestational age, and 
gestational age, parity, maternal age, socioeconomic status and mode of 
delivery. 
† Gestational age is adjusted for birth weight for gestational age, parity, 
maternal age, socioeconomic status and mode of delivery. 
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Being born SGA (<3
rd
 percentile) and moderately SGA (3
rd
 to <10
th
 percentile), 
increased the risk of BE almost 3-fold and 2-fold, respectively (Table 2). Analyzing the 
categories of birth weight for gestational age as a continuous variable, each stepwise 
increase in category resulted in OR 0.8 (95% CI 0.7-0.9, p for trend = 0.003). This can 
be interpreted as a protective effect of almost 17% per group from the smallest to the 
largest. The effect of being SGA was stronger among those with long segment BE as 
compared to those with short segment BE (OR 2.7, 95% CI 1.1-6.6 and OR 1.7, 95% 
CI 0.6-4.3, respectively) but the point estimates were not significantly heterogeneous (p 
for interaction = 0.63).  
 
5.3 GESTATIONAL AGE AT BIRTH AND RISK OF EAC 
The results from the two studies with EAC as the main outcome point in the same 
direction; gestational age at birth seems to affect the risk of EAC development later in 
life. There was a non-significant trend in both studies of increasing risk of EAC with 
decreasing gestational age. 
 
5.3.1 Study I 
In study I there were 67 cases of EAC, 93 cases of cardia adenocarcinoma and 50 cases 
of esophageal squamous cell carcinoma, and a total of 474 matched controls. 
Gestational age ≤38 weeks and risk of EAC was associated with an OR of 1.2 (95% CI 
0.5-2.7). No associations were found between relative birth weight for gestational age 
and risk of EAC. Gestational age ≤38 weeks was associated with a slight increase in 
risk of cardia adenocarcinoma (OR 1.3, 95% CI 0.7-2.4) and there was a statistically 
significant trend of a protective effect with increasing gestational age (p-value = 0.001).  
No association was evident between gestational age or relative birth weight, and 
subsequent risk of esophageal squamous cell carcinoma. 
 
5.3.2 Study IV 
In study IV there were 240 cases of EAC, 237 cases of cardia adenocarcinoma, 257 
cases of esophageal squamous cell carcinoma, and a total of 1799 matched controls. 
Gestational age <37 weeks and risk of EAC was associated with an OR of 1.9 (95% CI 
1.0-3.6). Modeling gestational age as a continuous variable was associated with a 13% 
increased risk per week earlier birth than birth at term (OR 1.1, 95% CI 1.0-1.2), equal 
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to a risk increase of 40% per month of prematurity. There was no evident association 
between gestational age and any of the other two tumor types. 
No association was evident between birth weight for gestational age or ponderal index, 
and any of the three tumor types studied. 
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6 DISCUSSION 
6.1 METHODOLOGICAL CONSIDERATIONS 
6.1.1 Study design  
We chose to do case-control studies as we deemed it the only feasible design. A 
randomized clinical trial would be impossible and unethical as you cannot randomize 
or induce the exposures preterm birth and SGA, nor can you randomize or induce 
pregnant women to preterm delivery by some intervention. Moreover, following-up a 
cohort of newborns, both term and preterm, until they are diagnosed with the outcome 
of interest many years later would be virtually impracticable.  
All our studies can be said to be nested case-control studies as we had strict definitions 
as of the source population. In this way we were certain that the controls came from the 
same source population, and the same study base, that gave rise to the cases. 
 
6.1.2 Internal validity 
Internal validity is a description of whether the study at hand has succeeded in showing 
what it set out to show. There are two principally different threats to the internal 
validity of a study, systematic error also known as bias (selection bias, information 
bias, confounding etc.) and random error (the effect of chance variability). 
 
6.1.2.1 Confounding 
Confounding is a type of bias that confuses or distorts the results of a study. A 
confounder is a variable that is linked to the exposure as well as the outcome, but it is 
not an intermediate in the causal pathway
181
. A confounder is taken care of by adjusting 
for it in the analysis. 
Possible confounders in our studies are for example BMI, tobacco smoking status, 
socioeconomic status, co-morbidities and level of symptoms of GERD.  We did not 
have information on any of these factors, as we only had access to our cases diagnosis 
and exposure data from the birth records of cases and controls. It is likely that these 
variables above are intermediate factors in the causal pathway from preterm or SGA 
birth to inflammation and cancer of the esophagus, and thus not confounding factors. 
We can only speculate as to how this lack of information affects our results. 
 
6.1.2.2 Detection bias  
Detection bias arises when an outcome is more commonly found in one group 
compared to another, due to extra attention paid to that group. In study II for example, 
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we cannot completely exclude the possibility that preterm born or SGA individuals are 
seen by their doctor more often than infants born at term, and for that reason more often 
diagnosed with esophagitis. This is discussed in depth in the article. For the remaining 
studies there are no obvious reasons for any detection bias. 
 
6.1.2.3  Selection bias 
Selection bias occurs when there is distortion in the process of selecting study subjects 
or from factors influencing the participation in a study, resulting in a different relation 
between exposure and outcome in those in the study and those not in the study
183
. In a 
case-control study, the selection of controls is the key to avoid selection bias. 
In our studies, cases were extracted from registers with regional or nationwide 
coverage. Anyone with the disease of interest ought to have had similar chance of 
ending up in the register and hence be an eligible case in our studies. Controls were 
selected among individuals born in the same hospitals as the cases, which ought to have 
affected neither exposure status nor outcome. These factors minimize the risk of 
selection bias in our studies.  
A special type of selection bias is survivor bias
183
. Most likely did many of the exposed 
individuals (preterm born or SGA) born in the early 20
th
 century, die before reaching 
adulthood when they would possibly have become eligible as study subjects. This leads 
to, together with life itself, that the effects of early life exposures often diminish with 
time i.e. older age of the study subjects. What was the reason for the survivors staying 
alive? We can only speculate of a kind of survival advantage perhaps in line with 
‘survival of the fittest’. 
 
6.1.2.4 Information bias 
Information bias, also called misclassification, arises when the measurement of 
exposure or outcome is dependent on other variables, or on errors in the measurement 
of other variables. Misclassification can be differential or non-differential, depending 
on whether the measurement error is equally distributed among the cases and controls 
or not. Non-differential misclassification mainly makes the comparison groups more 
alike and thus dilutes the association between the exposure and outcome, resulting in a 
bias towards the null. The effect of differential misclassification can either enhance or 
diminish an existing effect, or create a non-existing effect
181, 183
. 
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6.1.2.4.1 Misclassification of exposure 
The risk of misclassification of birth weight is very low, while the risk of 
misclassification of gestational age is considerably larger. The mother estimated the 
date of her last menstrual period, and gestational age was calculated from that date. It is 
possible that mothers misremembered, had bleedings in early pregnancy that were 
mistaken for menses, or that she purposely gave a forward-dated date to avoid having a 
child out of wedlock. This potential misclassification ought to be non-differential and 
independent, and if anything lead to a larger number of LGA infants. All exposure data 
was entered into the medical records prospectively, thus virtually precluding the risk of 
differential misclassification. 
 
6.1.2.4.2 Misclassification of disease 
For study I and IV cases were recruited from the Cancer Register that is 98% complete 
and there are unlikely any false negative cases of EAC in the population
109
. In study II 
cases were recruited from the Patient Register, and we validated the esophagitis 
diagnosis to be 95% accurate
189
. The prevalence of esophagitis in the population is 
estimated to 10%
59
, and the resulting bias from this group of false negatives among the 
controls will influence the result towards the null
183
. Cases for study III were all 
confirmed by histopathology as being intestinal metaplasia, giving the registers a high 
specificity. The incidence of BE in the populations is estimated to be 1.6%
83
, resulting 
in a small amount of false negative individuals among the controls and a low risk of 
misclassification bias. 
 
6.1.2.5 Random errors 
Any study result may be caused by chance or random error, and there are two types of 
random error. Type I or α error leads to an erroneous rejection of a ‘true’ null 
hypothesis and results in a false positive conclusion. The α-level or significance level is 
often set to 0.05. A Type II or β error leads to failure to reject a ‘false’ null hypothesis, 
and a false negative conclusion. The value of β is decided in advance, and is used in the 
power calculation to decide the sample size. By increasing the size of a study the 
statistical power and precision of a study is increased, thus reducing the risk of random 
error. With increasing sample size comes decreasing width of the confidence interval 
and smaller p-value, as indications of precision. The α and the β values are related to 
one another and the levels of them needs to be set with this in mind, as well as which 
statistical model is being used and the plausibility of the hypothesis tested. 
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In study I and IV the sample sizes were rather small resulting in confidence intervals 
including 1 and p-values>0.05, and a low statistical power. In studies II and III the 
sample sizes were larger, leading to less wide CI’s and statistically significant p-values.   
 
6.1.3 Generalizability 
Generalizability or external validity, is the concept of whether results can be 
generalized to another population than the one specified in the study. This is a key 
concept in research, based on biological plausibility, with practical as well as 
economical aspects
181, 183
. Generalizability depends mainly on the internal validity of a 
study, and on the population used; do differences between populations change the 
results? 
Our studies had sound internal validity and were population-based, restricted to 
individuals born in Sweden. Sweden is a country with high quality health care that is 
equally accessible for all, and with an infant mortality rate that has been lowered over 
the years. These facts might hamper generalizability to populations with higher infant 
mortality, or to birth cohorts within Sweden with better infant survival. It might also be 
difficult to generalize our results to populations with different access to health care.  
 
6.2 POSSIBLE BIOLOGICAL MECHANISMS 
From epidemiologic findings it is difficult to draw conclusions about biological 
mechanisms or causal pathways. Biological inference stems mainly from experimental 
research. Here we present some speculations regarding possible mechanisms, linking 
gestational age and size at birth to the esophageal health of the adult individual. 
  
6.2.1.1 Preterm born are prone to cancer? 
The hypothesis generating cohort study showed that apart from testicular cancer, breast 
cancer and EAC, there were no other tumor types that were overrepresented in that 
cohort of preterm and low birth weight infants (unpublished data)
190
. To our knowledge 
there are no other studies indicating a generally increased risk of cancer among preterm 
born individuals.  
 
6.2.1.2 The Barker hypothesis 
Also called the thrifty phenotype hypothesis, it was first presented by D. Barker in 1992 
based on his work in the late 1980’s and early 1990’s191, 192. He suggested that intra-
uterine growth restriction, the most common cause for low birth weight and SGA, leads 
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to adaptations in the fetus to a nutrient deprived environment. Once the fetus is born, 
these adaptations lead to chronic diseases like the metabolic syndrome, cardiovascular 
diseases and diabetes mellitus
193
. That the metabolic syndrome can lead to obesity is 
known, and also that obesity is a risk factor for GERD. The exposed cases in our 
studies could have been obese to a larger extent than the non-exposed cases
194
, and 
obesity could thus be a link in the causal pathway between preterm birth or SGA and 
GERD related complications.  
 
6.2.1.3 Pyloric stenosis  
This is a condition that causes severe vomiting in infants due to a hypertrophy of the 
pyloric sphincter, at the outlet of the stomach. There is a clear male predominance and 
it is also more common among preterm born and SGA infants
195
. Among infants born 
preterm, male infants are in general more vulnerable than female
18
. Can this indicate an 
increased vulnerability also in the gastrointestinal tract of male preterm born infants?  
 
6.2.1.4 Damages from stress? 
Not all preterm infants end up in an intensive care unit after birth, but some do. It is 
common in adults and children in intensive care units to present with gastrointestinal 
bleeding and lesions due to stress
196, 197
. Although most of these stress induced lesions 
heal in a few days
198
, they could perhaps affect the esophageal mucosa in the long term 
as well. 
 
6.2.1.5 Feeding tubes  
Most infants need assisted feeding before they reach a gestational age of 34 weeks. In 
Sweden nasogastric tubes have been used for feeding since late 1940’s (Personal 
communication: Anna-Karin Edstedt Bonamy November 2012). It has been showed 
that nasogastric tubes placed with its tip inside the stomach increases the incidence of 
GERD in a preterm population
133
.   
 
 
 
6.3 FINDINGS & IMPLICATIONS 
The data in this thesis suggests that gestational age and size at birth matters for the 
esophageal health later in life. The findings in the four studies are not entirely 
consistent as the exposure variable resulting in an increased risk varied between 
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preterm birth, SGA and low birth weight. Furthermore, we lack data to evaluate the 
possible pathologic mechanisms behind the associations, and we can only speculate 
regarding any potential causal links. Knowing the long term effect of prematurity and 
SGA on other organ systems in the body, it is not impossible to imagine a negative 
effect on the gastrointestinal tract as well.  
We speculate that the most plausible biological mechanism that links preterm birth to 
esophageal inflammation, metaplasia and cancer later in life is GER. Either the 
association is mediated through an extended period of exposure to reflux as it starts 
earlier in the preterm infant, or because the refluxate is more toxic to the preterm or 
SGA infant’s esophageal mucosa than it is to a mucosa in an infant born at term. There 
is a study showing symptomatic esophagitis becoming asymptomatic without treatment 
but with remaining pathology in the mucosa
199
. This could indicate that pathology 
might arise early in life and continue to exist but asymptomatic.  
The clinical implications of our results could include an increased awareness of that the 
effects of gestational age and size at birth possibly continues into adulthood, and this 
especially with regard to individuals presenting with GERD symptoms. But I would 
like to suggest some further studies to elucidate the biological mechanisms, before any 
preventive or treatment suggestions can be made. 
 
6.4 SUGGESTIONS FOR FUTURE RESEARCH  
 Future studies could focus on: 
- What does the esophageal mucosa of preterm infants actually look like? It 
could be an explorative case report of infants born preterm or it could be 
designed as a case-control study looking at esophageal biopsies from preterm 
compared to term born infants. Furthermore, it would be very interesting to 
examine biopsies from preterm individuals with GERD, compared to biopsies 
from term born infants with GERD. Are there histopathological differences 
between the groups?  
- Could the findings on esophagitis be repeated in 10 years time, when most 
infants with GERD probably will have been treated with antacids during the 
neonatal period? 
- Is there an increased risk of other gastrointestinal diseases in adulthood among 
individuals born preterm or SGA, like inflammatory bowel disease or Celiac 
Disease? This could be explored in a case-control study. 
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- What is the actual mechanism behind the association between preterm birth 
and inflammation of the esophagus? This needs to be studied at a molecular 
level; perhaps genetic studies, and most likely experimental studies of animal 
models. Knowledge of the potential mechanisms could enable early detection 
of precancerous lesions, and potentially development of prophylactic 
strategies. 
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7 CONCLUSIONS 
In this work we have explored a hypothesis divided into three research questions, by 
performing four separate studies. This is to our knowledge the first time that gestational 
age and size at birth are evaluated as possible risk factors for esophageal inflammation, 
metaplasia and adenocarcinoma later in life. From our work we conclude that: 
 
1) Being born preterm and being born small for gestational age might increase 
the risk of being diagnosed with esophagitis later in life.  
 
2) The association between preterm birth and being born small for gestational 
age and risk of esophagitis was strongest among those diagnosed before 10 
years of age. 
 
3) Being small for gestational age at birth or having a birth weight below 2,500 
grams might increase the risk of being diagnosed with BE as an adult, while 
no such effect was seen for gestational age alone. 
 
4) Gestational age at birth might influence the risk of EAC and also cardia 
adenocarcinoma as an adult. Our results indicate a dose-response relation 
between gestational age at birth and risk of EAC, with an increasing risk per 
week earlier birth as compared to birth at term. 
 
5) No association was evident in our material for age or size at birth and risk of 
esophageal squamous cell carcinoma later in life. 
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING  
8.1 SYFTE  
I den här avhandlingen har vi försökt besvara frågan om för tidig födsel eller att vara 
liten för tiden vid födseln, kan påverka risken att drabbas av inflammation, 
cellomvandling eller körtelcancer i matstrupen som vuxen.  
 
8.2 BAKGRUND  
8.2.1.1 Historik och förklaringsmodell 
Idén bakom avhandlingens fyra delarbeten föddes ur en studie baserad på en stor grupp 
individer som var födda för tidigt eller med låg födelsevikt. Gruppen följdes till vuxen 
ålder, då man fann en 7-faldigt ökad risk för körtelcancer i matstrupen (EAC). EAC är 
en tumörform där förekomsten ökar oförklarligt i många länder, och sura uppstötningar 
är den största riskfaktorn. De som föds för tidigt har mer sura uppstötningar än barn 
födda i fullgången tid, och förklaringsmodellen var att de tar större skada av 
uppstötningarna och därför får mer cancer som vuxna. Förstadier till EAC är 
inflammation och cellförändringar i matstrupen, och vi valde att studera även dessa 
sjukdomar för att få till en ’röd tråd’ i avhandlingen. 
 
8.2.1.2 Tidig födsel och liten för tiden 
I Sverige föds varje år ca 80-140,000 barn (Figur 2), varav 5-6% föds för tidigt (Figur 
3). Data från år tidigare än 1973 är osäkra, då inget offentlig medicinskt register över 
födslar fanns före dess. Spädbarnsdödligheten har sjunkit drastiskt sedan seklets början, 
pga. förbättrad mödra-, förlossnings-, och neonatalvård. För tidig födsel är att födas 
innan vecka 37 (Figur 1). Bland orsakerna till att födas för tidigt finns inflammation 
och sjukdomar hos mamman eller fostret, och missbildningar. Födelsevikt för tiden är 
ett mått på barnets tillväxt, de flesta spädbarn har en adekvat vikt för tiden (AGA) och 
ca 3% föds liten för tiden (SGA). Att vara för tidigt född kan innebära att man även är 
SGA, men det måste inte vara så. Bland orsakerna till att födas SGA är 
kromosomavvikelser hos fostret, att mamman röker eller är undernärd, samt dåligt 
blodflöde och funktion i moderkakan. Majoriteten av de för tidigt födda eller SGA 
födda klarar sig till vuxen ålder utan några fysiska men.  
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8.2.1.3 GERD 
Reflux av maginnehåll upp i halsen eller munnen är vanligt i den vuxna befolkningen, 
men även hos barn. Det är när övre magmunnen (lower esophageal sphincter, Figur 4) 
slappnar av som mat passerar ner och luft eller vätska kan passera upp. Har man 
uttalade besvär som t.ex. halsbränna, smärta bakom bröstbenet eller sur smak i munnen 
så kallas det för gastroesofagal refluxsjukdom (GERD), ca 15-40% av den vuxna 
befolkningen i västvärlden lider av detta. Efter en längre tid med GERD kan det uppstå 
inflammation i matstrupen, detta kallas esofagit och finns hos ca 10-15% av vuxna i 
västvärlden, oavsett om de har symtom eller inte (Figur 6A). Hos vissa individer med 
GERD kan utvecklingen fortsätta till Barretts esofagus (BE). BE innebär att cellerna i 
matstrupen har förändrats och bytt både utseende och funktion, som en anpassning till 
den sura miljön med reflux (Figur 6C). Slutligen kan BE hos ett fåtal individer, man vet 
inte hos vilka eller varför, fortsätta att förändras och tillslut omvandlas till EAC (Figur 
6D). Cancerceller kan växa till ohämmat, de uppvisar respektlöshet mot sin omgivning 
och har möjlighet att skapa egna blodkärl. EAC drabbar ca 200 personer per år i 
Sverige (Figur 7), fler män än kvinnor drabbas och endast 15% av dem lever 5 år efter 
diagnosen. Kända riskfaktorer för GERD är manligt kön, hög ålder, bukfetma, rökning 
och ärftlighet. GERD är en riskfaktor och gemensam nämnare för esofagit, BE och 
EAC. Antalet upptäckta fall av esofagit, BE och EAC ökar i västvärlden och har gjort 
så de senaste 40 åren. Ingen har hittills kunnat förklara vad denna ökning beror på.  
Barn som är födda för tidigt har mer reflux än barn födda i fullgången tid. GERD finns 
även bland barn, i en utsträckning som troligen är lägre än hos vuxna. GERD är 
troligen en kronisk sjukdom som startar i barndomen, och sedan ger symtom i perioder, 
och fortsätter upp i vuxen ålder. 
 
8.3 PATIENTER OCH METODER  
Samma studiedesign är använd i alla fyra delarbeten, som är s.k. fall-kontroll studier. 
Riskfaktorerna, eller exponeringarna, har varit liknande i alla delarbeten; ålder vid 
födseln räknad från datum för sista mens (gestationsålder), vikt vid födseln och ett mått 
på storlek vid födseln. Sjukdomen, eller utfallet, och därmed definitionen av vem som 
blir fall har varit olika; esofagit, BE och EAC. Fallen jämförs mot kontroller, som är 
personer från samma population som gav upphov till fallen. Vilka som blir fall, hur 
man samlar in fall och kontroller, och vilka exponeringar man undersöker väljs innan 
studien startar. Vi hade 3 eller 5 kontroller per fall, och i alla delarbeten var 
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kontrollerna matchade “sin” fallperson för ålder, kön och födelseort, vilket betyder att 
dessa variabler hade samma värde hos fall och kontroll.  
Delstudie I och IV: Fallen kom från Cancer Registret. Alla i Sverige som fått diagnosen 
EAC, körtelcancer i cardia (Figur 4) och skivepitelcancer i matstrupen 1994-1997 och 
som hade en förlossningsjournal ingick i studie I, och på motsvarande sätt 1998-2004 
för studie IV. Information om födelseålder och vikt mm, hämtades ur 
förlossningsjournalen. Som kontrollpersoner valdes 3 matchade individer som föddes 
efter fallet och skrevs ut levande från sjukhuset.  
 Delstudie II: Alla individer med diagnosen esofagit i Patientregistret 1973 – 2007 och 
som även fanns med i Medicinska Födelseregistret (MFR) utgjorde fall i studien. 5 
matchade kontroller per fall plockades slumpmässigt ur MFR.  
Delstudie III: Fallen utgjordes av individer som fått diagnosen BE åren 1986-2006 på 
Kalmar Länssjukhus och 1992-2007 på Ersta Sjukhus, Stockholm. Endast de individer 
där vi kunde hitta en förlossningsjournal ingick som fall i studien.  Som kontroller 
valdes 3 matchade individer som föddes efter fallet och skrevs ut levande från 
sjukhuset.  
I alla studier har vi analyserat data med konditionell logistisk regression och beräknat 
odds kvot (OR) och 95% konfidens intervall (KI). Mjukvaran heter STATA IC 11 och 
IC 12, från StataCorp, College station, Texas, USA.  
 
8.4 RESULTAT  
Delstudie I: I denna studie inkluderades 67 fall av EAC, 93 fall av körtelcancer i cardia, 
50 fall av skivepitelcancer i matstrupen samt 474 kontroller. Vi fann ingen uppenbar 
riskökning för EAC av varken låg gestationsålder eller av låg relativ vikt vid födseln 
(jämförbart med SGA). Vi fann ett omvänt samband mellan gestationsålder och risken 
för körtelcancer i cardia, dvs. att vara född med en gestationsålder ≥41 veckor kan ha 
en skyddande effekt. Vi fann inget samband mellan gestationsålder eller vikt vid 
födseln och skivepitelcancer i matstrupen.  
Delstudie II: 7,358 fall och 34,094 kontroller inkluderades i studien. Vi fann en 7-
faldigt ökad risk hos barn födda före vecka 32 och en 2-faldigt ökad risk hos de som 
var SGA, för att diagnosticeras med esofagit innan 10 års ålder (OR 6.8, 95% KI 4.7-
10.0 respektive OR 2.0, 95% KI 1.6-2.5). Då vi analyserade hela studiepopulationen 
oberoende av ålder vid diagnos, fann vi en knappt 3-faldigt ökad risk bland de som var 
födda före vecka 32 och en 50% ökad risk hos de som var SGA (OR 2.7, 95% KI 2.2-
3.5 respektive OR1.5, 95% KI 1.3-1.7).  
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Delstudie III: 331 fall och 852 kontroller inkluderades i studien. Vi fann att SGA var 
associerat med en 3-faldigt ökad risk (OR 3.0, 95% KI 1.4-6.4) och de som vägde 
2,500 gram eller mindre vid födelsen hade en 8-faldigt ökad risk att diagnosticerad med 
BE som vuxna (OR 8.2, 95% KI 2.8-23.9). För variabeln gestationsålder sågs ingen 
koppling till BE.  
Delstudie IV: I denna studie inkluderades 240 fall av EAC, 237 fall av körtelcancer i 
cardia, 257 fall av skivepitelcancer i matstrupen samt 1799 kontroller. För varje vecka 
tidigare födsel än i fullgången tid (40 veckor) ökade risken för EAC med 13% (OR 1.1, 
95% KI 1.0-1.3), eller ca 40% riskökning per månad för tidig födsel. Inget statistiskt 
signifikant samband sågs mellan gestationsålder och körtelcancer i cardia eller 
skivepitelcancer. Vi fann inte någon association mellan SGA eller risk för EAC, 
körtelcancer i cardia eller skivepitelcancer. 
 
8.5 SLUTSATSER  
Våra studier har visat att gestationsålder och storlek vid födelsen kan påverka risken för 
inflammation, cellförändringar och körtelcancer i matstrupen senare i livet. Vår hypotes 
är att denna riskökning kan vara orsakad av GERD, då de för tidigt födda barnen har 
mer reflux under sitt första år i livet, och eventuellt även senare också. Vi föreslår som 
förklaringsmodell hur reflux kan skada, att det antingen sker genom att cellerna är 
omogna och blir skadade av att utsättas för reflux, eller att de utsätts för en längre tid av 
reflux då den börjar tidigare i livet, än jämförelsegruppen individer födda i fullgången 
tid.  
Våra studier visar ett samband på populationsnivå, och säger inte någonting om risken 
för den enskilda individen. Vidare så är sambandet statistiskt, och vi kan endast 
spekulera om de biologiska mekanismerna som kunde förklara fynden. Utöver GERD 
finns det troligen fler verksamma faktorer i orsakskedjan.  
Styrkan med våra studier är att de är genomförda på ett metodologiskt och statistiskt 
korrekt vis, egentligen på det enda vis dessa samband kan undersökas. Förhoppningsvis 
kan resultaten föra med sig en ökad medvetenhet hos läkare om att gestationsålder och 
storlek vid födseln spelar roll även senare i livet, och att extra uppmärksamhet riktas 
mot individer som fötts för tidigt eller SGA som i vuxen ålder har besvär av GERD. 
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